MARKET
IPO

SCTX

Scribe Therapeutics, Inc.
SCTX
NASDAQ
Upcoming IPOs
Expected Listing Date: 2026-07-24
P/E
P/S
P/B
MARKET CAP
INDUSTRY
-9.21
-
-
226.55M
Biotechnology & Medical Research
2026-07-02
Public Filing
View Prospectus
Pending
Offering
Price Range: 14.00
Shares to be Issued: 7150.00K
2026-07-23
Offering End Date
Offering Price: 14.00
Post IPO Outstanding: 16.18M
2026-07-24
Listed
No Data
About SCTX
Scribe Therapeutics, Inc. is a clinical-stage biotechnology company engineering purpose-built in vivo CRISPR technologies designed to extend healthy lifespan through disease prevention and durable therapeutic intervention. It focuses on cardiovascular and metabolic (CVM) diseases with initial programs to address the key drivers of atherosclerotic cardiovascular disease (ASCVD). The Company's lead product candidate, STX-1150, is an epigenetic silencing therapy that is based on its ELXR technology and is designed to durably lower LDL-C for years to decades by repressing the expression of PCSK9, a genetically and clinically validated target. STX-1150 is designed to achieve long-lasting therapeutic benefit without permanently altering the underlying DNA sequence. Its pipeline also includes STX-1200 and STX-1400, target two additional lipid drivers of ASCVD, elevated Lp(a) and severely high triglycerides, by editing the LPA and APOC3 genes, respectively.

Webull offers Scribe Therapeutics, Inc. stock information, including NASDAQ: SCTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SCTX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SCTX stock methods without spending real money on the virtual paper trading platform.